Le Lézard
Classified in: Health
Subjects: SVY, TRI

Large Study shows 230 Times Higher One Year Cancer Risk If Tumor Cell Clusters are Detected in Blood of Normal Individuals - Datar Cancer Genetics


MUMBAI, India and LONDON, Sept. 29, 2020 /PRNewswire/ -- A landmark study published in the American Association of Cancer Research's (AACR) prestigious journal 'Cancer Prevention Research' has shown that it is possible to identify healthy individuals with higher risk of cancer based on a simple blood draw. The study reports that seemingly normal, asymptomatic middle-aged men and women with no history of cancer but having detectable clusters of Circulating Tumor Cells (abbreviated as 'C-ETACs') in their blood have a 230 times higher one year risk of developing cancer as compared to individuals where such clusters were undetectable in blood samples.

Datar Cancer Genetics Logo

In this multi-institutional international collaborative study led by Datar Cancer Genetics, the investigators screened more than 10,000 asymptomatic individuals for detection of C-ETACs and subsequently followed up on these individuals over a period of one year. Simultaneously, blood from more than 4000 cancer patients with various malignancies ('solid organ cancers') was also studied. The study findings revealed that C-ETACs were almost invariably found in cancer patients (> 90%) but were extremely rare (<5%) in normal individuals with no diagnosis or symptom of cancer. Subsequently, over a one-year follow-up, 3.475% of C-ETAC positive normal individuals were diagnosed with various cancers as opposed to 0.015% of C-ETAC negative individuals thus yielding a 230-fold increase in one year risk of cancer diagnosis.

The study is significant because early detection of cancer and risk stratification of seemingly normal individuals remains an ongoing public health challenge. 9.6 million individuals worldwide succumb to cancer each year mainly because of late detection and even the World Health Organization in its 2014 Report has identified early detection as its major objective.

The C-ETAC detection technology and the test are developed by Datar Cancer Genetics using an innovative approach for selective destruction of non-cancer cells in the blood for harvesting C-ETACs. The accuracy of the test is 95.6% and covers more than 20 cancers including Breast, Lung, Ovarian, Stomach, Pancreatic, Colon and Prostate.

Commenting upon the results, Dr Tim Crook, Medical Oncologist at Broomfield Hospital, UK and one of the authors of the paper said that 'C-ETACs are virtually a non-invasive micro-biopsy that will enable high confidence screening and risk stratification of seemingly normal individuals. The technology represents a major advancement for early detection of cancer. The large size of the study is significant.'

The research is published online (https://doi.org/10.1158/1940-6207.CAPR-20-0322) .

About Datar Cancer Genetics

Datar Cancer Genetics is a leading cancer research corporation specialising in non-invasive techniques for better diagnosis, treatment decisions, and management of cancer. The Company's state-of-the-art cancer research centre is ILAC - NABL, ISO, CAP and CLIA ? USA accredited.

For More Information contact

Dr Vineet Datta - drvineetdatta@datarpgx.com  
Access Publication of the study at
https://doi.org/10.1158/1940-6207.CAPR-20-0322  
https://datarpgx.com/publications/

Website
datarpgx.com

Logo: https://mma.prnewswire.com/media/1086492/Datar_Cancer_Genetics_Logo.jpg


These press releases may also interest you

23 oct 2020
The liquid biopsy market is poised to grow by USD 4.02 billion during 2020-2024, progressing at a CAGR of almost 38% during the forecast period. The report on the liquid biopsy market provides a holistic update, market size and forecast, trends,...

23 oct 2020
The dPCR market is poised to grow by USD 518.69 million during 2020-2024, progressing at a CAGR of over 24% during the forecast period. The report on the dPCR market provides a holistic update, market size and forecast, trends, growth drivers, and...

23 oct 2020
Emerging leader in infused cannabis beverages BevCanna Enterprises Inc. announced today that the Company has received a capital injection of $750,000. The funds are the proceeds of a Unit private placement (the "Private...

23 oct 2020
The food recall warning issued on October 22, 2020 has been updated to include additional product information. This additional information was identified during the Canadian Food Inspection Agency's (CFIA) food safety investigation. Nature's Intent...

23 oct 2020
The Washington State Department of Health issued Eden Home Health of Spokane County, LLC a Certificate of Need to provide Home Health Care services in Spokane County on December 24, 2019.  Effective July 28, 2020, Eden Home Health of Spokane County,...

23 oct 2020
As someone who has spent a good portion of the last 20 years in scrubs, I definitely have my opinions on what I like and dislike! Comfort, pockets, and non-iron are my priorities. I also know that my coworkers have some strong feelings about their...



News published on 29 september 2020 at 02:00 and distributed by: